Literature DB >> 3842314

Cell surface antigens of melanocytes and melanoma.

A P Albino, A N Houghton.   

Abstract

One major focus of cancer immunology is the question of tumour-specific antigens, the existence of which has yet to be proven. The prime candidates for antigens that can be considered tumour-specific are the class 1 unique antigens that have been serologically defined on human malignant melanomas by antibodies from the tumour-bearing host. In addition to these antigens, intensive immunological, biochemical and genetic analyses of melanoma have permitted a rudimentary classification of other surface antigens expressed by this tumour type. Cell-surface antigens of melanoma can be grouped into three general classes: restricted antigens (i.e. antigens which are expressed by melanomas and astrocytomas) many of which are differentiation markers characterizing cells of neuroectodermal origin; antigens with intermediate distribution (i.e. antigens which are present on some cell tumour types but not on others and which show a limited distribution on normal tissues and cells); and antigens with broad distribution (i.e. antigens expressed by most human cells either malignant or normal). The detailed knowledge of the surface antigens (i.e. differentiation antigens and class 1 unique antigens) of melanoma cells has permitted a rational and coherent approach to assessing the possibility of immunological control of malignant melanoma in the clinic.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3842314

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  8 in total

1.  Expression of HLA-DR antigens on tumour cells does not contribute to skin reactivity to autologous cholesteryl hemisuccinate (CHS)-treated tumour cells in patients with metastatic melanoma.

Authors:  M Munzarová; D Zemanová; J Kovarík; Z Pacovský; A Rejthar; J Bártek
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  DNA content and MHC class II antigen expression in malignant melanoma: clinical course.

Authors:  J Zaloudik; M Moore; A K Ghosh; Z Mechl; A Rejthar
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

3.  The appearance, density and distribution of melanocytes in human embryonic and fetal skin revealed by the anti-melanoma monoclonal antibody, HMB-45.

Authors:  K A Holbrook; R A Underwood; A M Vogel; A M Gown; H Kimball
Journal:  Anat Embryol (Berl)       Date:  1989

4.  HLA-DR antigen expression on melanoma metastases and the course of the disease.

Authors:  M Munzarová; D Zemanová; A Rejthar; Z Mechl; V Kolcová
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  A distinct octamer-binding protein present in malignant melanoma cells.

Authors:  P M Cox; S M Temperley; H Kumar; C R Goding
Journal:  Nucleic Acids Res       Date:  1988-12-09       Impact factor: 16.971

6.  Establishment and characterization of a clear-cell sarcoma (malignant melanoma of soft parts) cell line.

Authors:  T Takenouchi; K Ito; T Kazama; M Ito
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

Review 7.  Mechanisms of differentiation in melanoma cells and melanocytes.

Authors:  D C Bennett
Journal:  Environ Health Perspect       Date:  1989-03       Impact factor: 9.031

8.  Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses.

Authors:  A P Albino; A N Houghton; M Eisinger; J S Lee; R R Kantor; A I Oliff; L J Old
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.